WallStSmart

Novartis AG ADR (NVS)vsSonida Senior Living Inc (SNDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 15333% more annual revenue ($56.69B vs $367.34M). NVS leads profitability with a 22.5% profit margin vs -27.1%. SNDA appears more attractively valued with a PEG of 2.04. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

SNDA

Hold

36

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.7Quality: 3.0
Piotroski: 2/9Altman Z: -0.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-68.7%)

Margin of Safety

-68.7%

Fair Value

$92.54

Current Price

$158.83

$66.29 premium

UndervaluedFair: $92.54Overvalued

Intrinsic value data unavailable for SNDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

SNDA2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
38.5%10/10

Revenue surging 38.5% year-over-year

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
4.152/10

Expensive relative to growth rate

SNDA4 concerns · Avg: 3.3/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Market CapQuality
$1.93B3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.833/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bull Case : SNDA

The strongest argument for SNDA centers on Revenue Growth, Price/Book. Revenue growth of 38.5% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : SNDA

The primary concerns for SNDA are PEG Ratio, Market Cap, Debt/Equity. Debt-to-equity of 1.83 is elevated, increasing financial risk.

Key Dynamics to Monitor

NVS profiles as a value stock while SNDA is a hypergrowth play — different risk/reward profiles.

SNDA carries more volatility with a beta of 0.76 — expect wider price swings.

SNDA is growing revenue faster at 38.5% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 36/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Sonida Senior Living Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Sonida Senior Living, Inc. develops, owns, operates and manages senior living communities in the United States. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?